Banks v. C.R. Bard, Inc.

CourtDistrict Court, M.D. Louisiana
DecidedJanuary 30, 2023
Docket3:17-cv-00193
StatusUnknown

This text of Banks v. C.R. Bard, Inc. (Banks v. C.R. Bard, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Banks v. C.R. Bard, Inc., (M.D. La. 2023).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF LOUISIANA THEDA BANKS CIVIL ACTION VERSUS 17-193-SDD-RLB C.R. BARD, INC. AND BARD PERIPHERAL VASCULAR, INC.

RULING Before the Court is the Motion in Limine to Exclude Testimony and Evidence of Recovery Filter Migration Deaths1 and Motion in Limine to Exclude Recovery Filter Marketing, Communications, and other Irrelevant and Improper Propensity Evidence2 filed by Defendants C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. (“Defendants”). An Opposition3 was filed by Plaintiff Theda Banks (“Banks”), to which Defendants filed a Reply.4 For the following reasons, the Motion is granted. I. BACKGROUND This is a products liability action that was remanded to this Court for a Plaintiff- specific trial from the multidistrict litigation captioned In re: Bard IVC Filters Products Liability Litigation, MDL 2641, in the United States District Court for the District of Arizona. (the “MDL”).5 Plaintiff brings this action for personal injuries suffered after being implanted with an Inferior Vena Cava (“IVC”) filter medical device manufactured by Defendants. An IVC filter is a device that is designed to filter or “catch” blood clots that travel from the lower

1 Rec. Doc. 129. 2 Rec. Doc. 136. 3 Rec. Doc. 149. 4 Rec. Docs. 167, 168. 5 See In re Bard IVC Filters Prod. Liab. Litig., No. MDL 15-02641-PHX DGC, 2018 WL 495188 (D. Ariz. Jan. 22, 2018). portions of the body to the heart and lungs. On October 29, 2007, Plaintiff was implanted with a Bard IVC filter known as the G2.6 Banks’s filter remained in place without known complication until March 2016, when it failed by severely tilting, migrating downward, and perforating her IVC wall, as well as her pancreas and aorta.7 Before that, in 2002, FDA cleared the Recovery filter, Bard’s first-generation

retrievable filter, for commercial marketing, which lasted from 2003 to 2005.8 During this time, Bard received reports of the Recovery experiencing cephalad (upward) migration to a patient’s heart resulting in death.9 Bard issued a Crisis Communication Plan (“CCP”) to guide Bard’s response to potential media inquiries into the reported Recovery migration deaths.10 Evidence suggests that the CCP was never used due to a lack of inquiries.11 Bard also sent sales communiques to its sales force for informational use in responding to questions concerning the deaths.12 Around this time, a sales representative, Jason Greer, sent an email to a senior marketing manager reflecting on events surrounding the Recovery complications and telling the manager that she held together “a terrible situation . . . with scotch tape, smoke, mirrors, crying, etc.”13

Bard introduced the G2 (Bard’s second-generation retrievable filter) to the market in late 2005.14 Based on clinical experience with the Recovery, Bard made several significant design changes to the G2 aimed at improving fracture and migration

6 Stipulated to by parties. Rec. Doc. 106, p. 6. 7 Rec. Doc. 95-6, p. 12. 8 Id., p. 15. 9 Id., p. 16. 10 Rec. Doc. 136-8. 11 Rec. Doc. 136-7 at 64:4–11. 12 Rec. Docs. 136-9, 136-10. 13 Rec. Doc. 136-11. 14 Rec. Doc. 95-6, p. 11. resistance.15 Those changes almost entirely eliminated cephalad migrations.16 Bard now moves to exclude evidence of the Recovery migration deaths as well as the CCP, sales communiques, and Greer email that Bard produced in response to those deaths. Bard argues that this evidence is irrelevant and unduly prejudicial because it does not involve the filter or specific complications at issue. Banks responds

that this evidence is necessary to establish Bard’s awareness of problems with the G2 filter and to fully explain the G2 filter’s design history. II. LAW AND ANALYSIS Federal Rule of Evidence 401 provides that evidence is relevant if: “(a) it has any tendency to make a fact more or less probable than it would be without the evidence; and (b) the fact is of consequence in determining the action.” “Irrelevant evidence is not admissible.”17 Rule 403 provides that relevant evidence may nevertheless be excluded if “its probative value is substantially outweighed by the danger of unfair prejudice, confusion of the issues, or misleading the jury, or by considerations of undue delay, waste of time, or needless presentation of cumulative evidence.”18 The Court addresses

the relevance and prejudicial effect of each piece of evidence in turn. A. Evidence of Recovery Migration Deaths Bard seeks to exclude evidence of cephalad migrations by the Recovery Filter resulting in death. The Fifth Circuit has held that “[w]hen evidence of other accidents or occurrences is offered for any purpose other than to show notice, the proponent of that

15 Id., p. 17. 16 In re Bard IVC Filters Prod. Liab. Litig., No. CV-16-00782-PHX-DGC, 2018 WL 1993767, at *2 (D. Ariz. Apr. 27, 2018). 17 Fed. R. Evid. 402. 18 Fed. R. Evid. 403. evidence must show that the facts and circumstances of the other accidents or occurrences are ‘closely similar’ to the facts and circumstances at issue”—otherwise known as “the ‘substantial similarity’ requirement for admissibility.”19 In the Fifth Circuit, “[t]he question of admissibility of substantially similar accidents is necessarily determined on a case-by-case basis, with consideration to be given to any number of

factors, including the product or component part in question, the plaintiff’s theory of recovery, the defenses raised by the defendant, and the degree of similarity of the products and of the other accidents.”20 The circumstances in this case sharply differ from those surrounding the Recovery migrations. For one, this case does not involve a complication resulting in death. Nor does it involve cephalad migration of the entire G2 to the heart. Instead, Banks’s own evidence shows that her filter migrated in the opposite direction, “downward” towards her feet. The Court follows the conclusion, reached in two MDL bellwether cases, that “instances of cephalad migration resulting in death are not

substantially similar to complications experienced by the G2 [and subsequent Bard filters].” Ultimately, the key question in this case is whether Bank’s injuries were caused by a design defect in the G2 filter—not the Recovery. There is no evidence, beyond Banks’s conclusory allegations, that the Recovery deaths resulted from the same problematic design element that caused Banks’s injuries. As the MDL court

19 Johnson v. Ford Motor Co., 988 F.2d 573, 579-580 (5th Cir. 1993); accord Olivier v. Exxon Mobil Corp., No. 18-CV-568-SDD-EWD, 2022 WL 3010691, at *3 (M.D. La. July 29, 2022) (Dick, C.J.). 20 Brazos River Auth. v. GE Ionics, Inc., 469 F.3d 416, 426 (5th Cir. 2006). acknowledged, “cephalad migrations largely ceased due to changes made to the G2- line of filters.”21 Bard points out that in one bellwether trial, the Booker trial, the court concluded that evidence of cephalad migrations by a Recovery filter was necessary for the jury to understand the issues that prompted creation and design of the next-generation G2

filter.22 There, however, the MDL court did not apply the substantial similarity requirement used by courts in the Fifth Circuit. The defendants also opened the door to the Recovery evidence by arguing that the G2 was as safe and effective as the Recovery.23 Here, it does not appear that Defendants intend to make such an argument at trial.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Banks v. C.R. Bard, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/banks-v-cr-bard-inc-lamd-2023.